期刊
JOURNAL OF HEPATOLOGY
卷 79, 期 5, 页码 1317-1331出版社
ELSEVIER
DOI: 10.1016/j.jhep.2023.07.034
关键词
Farnesoid X receptor agonists; non-alcoholic steatohepatitis; liver fibrosis; randomized controlled trials; combination therapy
The farnesoid X receptor (FXR) is a bile acid-activated nuclear receptor that plays a crucial role in regulating various metabolic processes in the liver and intestine. FXR activation has emerged as a potential pharmacological target for the treatment of non-alcoholic steatohepatitis (NASH), a severe metabolic disorder with no approved pharmacological treatments. This review summarizes the preclinical and clinical features of the most advanced FXR agonists and evaluates their potential in NASH treatment.
The farnesoid X receptor (FXR), a bile acid (BA)-activated nuclear receptor highly expressed in the liver and intestine, regulates the expression of genes involved in cholesterol and bile acid homeostasis, hepatic gluconeogenesis, lipogenesis, inflammation and fibrosis, in addition to controlling intestinal barrier integrity, preventing bacterial translocation and maintaining gut microbiota eubiosis. Non-alcoholic steatohepatitis (NASH), an advanced stage of non-alcoholic fatty liver disease, is characterized by hepatic steatosis, hepatocyte damage (ballooning) and inflammation, leading to fibrosis, cirrhosis and hepatocellular carcinoma. NASH represents a major unmet medical need, but no pharmacological treatments have yet been approved. The pleiotropic mechanisms involved in NASH development offer a range of therapeutic opportunities and among them FXR activation has emerged as an established pharmacological target. Various FXR agonists with different physicochemical properties, which can be broadly classified as BA derivatives, non-BA-derived steroidal FXR agonists, non-steroidal FXR agonists, and partial FXR agonists, are in advanced clinical development. In this review we will summarize key preclinical and clinical features of the most advanced FXR agonists and critically evaluate their potential in NASH treatment.(c) 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据